Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rolf Fendel

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Nature Communications|May 26, 2021
Immune response to SARS-CoV-2 variants of concern in vaccinated individualsMatthias Becker, Alex Dulovic, Daniel Junker, et al.
Wiener Klinische Wochenschrift|August 11, 2021
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trialPeter G Kremsner, Philipp Mann, Arne Kroidl, et al.
Plos Pathogens|June 29, 2023
The exception that proves the rule: Virulence gene expression at the onset of Plasmodium falciparum blood stage infectionsJan Stephan Wichers-Misterek, Ralf Krumkamp, Jana Held, et al.
Nature Communications|May 5, 2021
Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trialZita Sulyok, Rolf Fendel, Bianca Eder, et al.
Ebiomedicine|October 1, 2024
PfSPZ Vaccine induces focused humoral immune response in HIV positive and negative Tanzanian adultsAnneth Tumbo, Freia-Raphaella Lorenz, Annie S P Yang, et al.
Plos Neglected Tropical Diseases|June 1, 2021
Exploratory analysis of the effect of helminth infection on the immunogenicity and efficacy of the asexual blood-stage malaria vaccine candidate GMZ2Odilon Nouatin, Juliana Boex Mengue, Jean Claude Dejon-Agobé, et al.
NPJ Vaccines|August 23, 2022
A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infectionBenjamin Mordmüller, Zita Sulyok, Mihály Sulyok, et al.
The Journal of Clinical Investigation|October 27, 2022
Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacityChristian Meyer Zu Natrup, Alina Tscherne, Christine Dahlke, et al.
The Lancet. Microbe|January 21, 2023
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2Merel J Smit, Adam F Sander, Maud B P A Ariaans, et al.
Nature Immunology|April 23, 2021
Systems analysis and controlled malaria infection in Europeans and Africans elucidate naturally acquired immunitySanne E de Jong, Vincent van Unen, Mikhael D Manurung, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Nature Communications|May 26, 2021
Immune response to SARS-CoV-2 variants of concern in vaccinated individualsMatthias Becker, Alex Dulovic, Daniel Junker, et al.
Wiener Klinische Wochenschrift|August 11, 2021
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trialPeter G Kremsner, Philipp Mann, Arne Kroidl, et al.
Plos Pathogens|June 29, 2023
The exception that proves the rule: Virulence gene expression at the onset of Plasmodium falciparum blood stage infectionsJan Stephan Wichers-Misterek, Ralf Krumkamp, Jana Held, et al.
Nature Communications|May 5, 2021
Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trialZita Sulyok, Rolf Fendel, Bianca Eder, et al.
Ebiomedicine|October 1, 2024
PfSPZ Vaccine induces focused humoral immune response in HIV positive and negative Tanzanian adultsAnneth Tumbo, Freia-Raphaella Lorenz, Annie S P Yang, et al.
Plos Neglected Tropical Diseases|June 1, 2021
Exploratory analysis of the effect of helminth infection on the immunogenicity and efficacy of the asexual blood-stage malaria vaccine candidate GMZ2Odilon Nouatin, Juliana Boex Mengue, Jean Claude Dejon-Agobé, et al.
NPJ Vaccines|August 23, 2022
A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infectionBenjamin Mordmüller, Zita Sulyok, Mihály Sulyok, et al.
The Journal of Clinical Investigation|October 27, 2022
Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacityChristian Meyer Zu Natrup, Alina Tscherne, Christine Dahlke, et al.
The Lancet. Microbe|January 21, 2023
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2Merel J Smit, Adam F Sander, Maud B P A Ariaans, et al.
Nature Immunology|April 23, 2021
Systems analysis and controlled malaria infection in Europeans and Africans elucidate naturally acquired immunitySanne E de Jong, Vincent van Unen, Mikhael D Manurung, et al.
Pageof 8